CUV.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 01:58):

Stats
Today's Volume	67 584.00
Average Volume	117 621
Market Cap	763.58M
EPS	$0 ( 2024-02-21 )
Next earnings date	( $0 ) 2024-08-26
Last Dividend	$0.0500 ( 2023-09-05 )
Next Dividend	$0 ( N/A )
P/E	26.74
ATR14	$0.0240 (0.16%)

Volume Correlation

Long: -0.36 (neutral)

Short: -0.01 (neutral)

Signal:(51.468) Neutral

Clinuvel Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clinuvel Pharmaceuticals Correlation - Currency/Commodity

0.62
( weak )

0.68
( moderate )

0.00
( neutral )

0.26
( neutral )

-0.71
( moderate negative )

Clinuvel Pharmaceuticals Financials

Annual	2023
Revenue:	$78.32M
Gross Profit:	$50.59M (64.59 %)
EPS:	$0.620

FY	2023
Revenue:	$78.32M
Gross Profit:	$50.59M (64.59 %)
EPS:	$0.620

FY	2022
Revenue:	$65.72M
Gross Profit:	$46.62M (70.93 %)
EPS:	$0.420

FY	2021
Revenue:	$47.98M
Gross Profit:	$43.26M (90.16 %)
EPS:	$0.513

Financial Reports:

No articles found.

Clinuvel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0400 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.0500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Clinuvel Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.06 - Increase likely (41.28%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0200	2018-09-21
Last Dividend	$0.0500	2023-09-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$0.185	--
Avg. Dividend % Per Year	0.00%	--
Score	3.17	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.06
Div. Directional Score	8.71	--

Next Divdend (Est)
(2024-07-01)

$0.0598 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.17

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NCC.AX	Ex Dividend Junior	2023-10-04	Semi-Annually	0.00%
ZIM.AX	Ex Dividend Knight	2023-09-01	Annually	0.00%
ENN.AX	No Dividend Player	2023-06-29	Annually	0.00%
PLS.AX	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
ALD.AX	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
GWA.AX	Ex Dividend Knight	2023-08-18	Semi-Annually	0.00%
S32.AX	Ex Dividend Junior	2023-09-14	Semi-Annually	0.00%
BPT.AX	Ex Dividend Junior	2023-09-04	Semi-Annually	0.00%
LLC.AX	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
TER.AX	Ex Dividend Junior	2023-06-08	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.371	1.500	2.58	3.86	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.176	1.500	9.16	10.00	[0.1 - 1]
payoutRatioTTM	0.0819	-1.000	9.18	-9.18	[0 - 1]
currentRatioTTM	6.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.38	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.321	1.500	3.77	5.66	[0.2 - 2]
debtRatioTTM	0.00505	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.725	2.00	9.64	10.00	[0 - 20]
debtEquityRatioTTM	0.00598	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.483	1.000	2.33	2.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	39.55	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	26.43	1.000	7.43	0	[1 - 100]
returnOnEquityTTM	0.176	2.50	9.46	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.725	2.00	9.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.314	1.500	2.14	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
payoutRatioTTM	0.0819	1.500	9.18	-9.18	[0 - 1]
pegRatioTTM	3.88	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.520	1.000	10.00	0	[0.1 - 0.5]
Total Score				7.06

Clinuvel Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.